Director, Search and Evaluation Cardiometabolic & Endocrinology (Seaport MA)
Merck Healthcare KGaA
Summary
Drive access to key external innovations from biotech/biopharma companies globally for Cardiometabolic, Fertility & Endocrinology (CM+F&E), enabling critical advancement of the company pipeline; search and evaluate external opportunities and lead scientific and technical assessment process for potential partners, acquisitions, or licensing deals.
Job description
Your Role
Drive access to key external innovations from biotech/biopharma companies globally for Cardiometabolic, Fertility & Endocrinology (CM+F&E), enabling critical advancement of the company pipeline; search and evaluate external opportunities and lead scientific and technical assessment process for potential partners, acquisitions, or licensing deals.
- Take full responsibility for Initial Assessments (IAs) as the initial step in a Due Diligence process with key functional experts and present high quality decision making documents to the Investment Board (IB) and lead respective multi-functional teams
- Partner with internal stakeholders to identify search priorities and support defining the CM+F&E partnering strategy
- Develop and keep overview of External Innovation landscape within investment priorities in alignment with the CM+F&E Therapeutic Areas
- Drive proactive search to identify assets of interest and potential partners and guide partner selection
- Select and prioritize opportunities for further evaluation in close collaboration with Business Development counterparts
- Maintain overview of search and evaluation activities in CM+F&E and maintain a longlist of potential opportunities
- Oversee and guide filtering of potential opportunities (e.g., unsolicited, VC portfolios, conferences); execute CDA and provide aligned feedback to stakeholders
- Benchmarking of potential partners based on aligned criteria to elucidate differentiation
- Build and maintain external network (e.g., biotech/pharma/VC) and represent/position us externally towards potential partners
- Collaborate with BD colleagues for partnering discussions to assess viability / feasibility of partnership
- Consult on assessment of risks and mitigations and ensure seamless transition of IA projects to DD Lead
- Drive identification of big rocks and consolidation of IB decision-making document to make a go/no-go decision
- Provide decision making documentation to IB and DRB level senior management to proceed into Due Diligence activities to assess Big Rocks or full data packages of external opportunities
Scope of People Responsibility
- Develop and mentor talents (e.g. GoGlobal Trainees and Short-Term Assignees)
- Lead multi-functional assessment teams to generate IAs, DD scopes
Who You Are
Minimum Qualifications: University degree (PhD) in pharmaceutical science or an equivalent qualification with high expertise, strong network, and substantial R&D experience in respective investment priority field.
Preferred Qualifications: 5+ years experience with 2+ years in BD&L / EI; thorough understanding of the pharmaceutical drug discovery/development process; scientific profile with substantial R&D experience; strong leadership acumen to lead cross functional teams to develop search scopes, External Innovation strategy and IAs; strong presentation skills enabling senior management decision making.
Requirements
- PhD in pharmaceutical science or equivalent qualification
- High expertise, strong network, and substantial R&D experience in investment priority field
- 5+ years experience
- 2+ years in BD&L / EI
- Thorough understanding of pharmaceutical drug discovery/development process
- Strong leadership acumen to lead cross functional teams
- Strong presentation skills enabling senior management decision making
Benefits
- Health Insurance
- Paid Time Off (PTO)
- Retirement Contributions
- Performance-Based Bonuses
Company overview
Merck Healthcare KGaA is the healthcare business sector of the Merck Group, a German multinational science and technology company headquartered in Darmstadt. Founded in 1668, Merck is the world's oldest operating pharmaceutical and chemical company. The Healthcare division focuses on developing innovative therapies across multiple therapeutic areas including oncology, neurology & immunology, fertility, and cardiovascular, metabolic, and endocrinological disorders. With approximately 62,557 employees globally, Merck Healthcare operates in more than 65 countries and generated 40% of the Group's sales in 2024. The company's oncology portfolio includes blockbuster products like Erbitux (cetuximab) for colorectal and head and neck cancers, Bavencio (avelumab) for urothelial carcinoma, and Tepmetko (tepotinib) for MET-altered cancers. In neurology, Mavenclad (cladribine) has achieved blockbuster status for treating relapsing multiple sclerosis, while the fertility division has helped bring over 6 million babies into the world through products like Gonal-f. Merck Healthcare combines a strong established business with specialty innovation, delivering a diversified portfolio of therapies to millions of patients worldwide.